NB-e101
Autosomal Dominant Retinitis Pigmentosa (adRP)
DiscoveryActive
Key Facts
Indication
Autosomal Dominant Retinitis Pigmentosa (adRP)
Phase
Discovery
Status
Active
Company
About Nerai Biosciences
Nerai Biosciences is a private, pre-clinical stage biotech founded in 2021 in Zurich, Switzerland. The company's core innovation is the MORPHEME platform, which integrates high-throughput directed evolution, functional screening, and machine learning to engineer novel CRISPR enzymes with superior specificity and activity. Nerai is advancing a proprietary pipeline of genome editing therapies for rare genetic diseases, with its lead program for Citrullinemia type 1 in in vivo lead optimization. The company is backed by non-dilutive grants and awards, positioning it to address previously inaccessible genetic mutations.
View full company profile